ArticleClinical and experimental immunology2006
Glomerular expression and elevated serum Bcl-2 and Fas proteins in lupus nephritis: preliminary findings.
Article in Clinical and experimental immunology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- The Antioxidant Activity ofAntioxidants (Basel, Switzerland) · 2023Article
- Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.Lupus science & medicine · 2020Article
- Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis.Clinical immunology (Orlando, Fla.) · 2017Review
- Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation.Arthritis & rheumatology (Hoboken, N.J.) · 2016Article
- Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus.Clinical and experimental immunology · 2015Article
- Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus.Disease models & mechanisms · 2014Review
- Antitumor effect and mechanism of an ellagic acid derivative on the HepG2 human hepatocellular carcinoma cell line.Oncology letters · 2014Article
- The effect of esculentoside A on lupus nephritis-prone BXSB mice.Archives of medical science : AMS · 2013Article
- Stronger Correlation between Interleukin 18 and Soluble Fas in Lupus Nephritis Compared with Mild Lupus.ISRN rheumatology · 2013Article
- Mesangial cell-specific antibodies are central to the pathogenesis of lupus nephritis.Clinical & developmental immunology · 2012Review
- Extracellular administration of BCL2 protein reduces apoptosis and improves survival in a murine model of sepsis.PloS one · 2011Article
- Systemic lupus erythematosus after thymectomy for myasthenia gravis: a case report and review of the literature.Clinical and experimental nephrology · 2010Review
- Article
- Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus: relation to the organ damage and lymphocytes apoptosis.Molecular biology reports · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed cell death (apoptosis) is involved in glomerular injuries leading to glomerulonephritis. Bcl-2 and Fas are proteins that promote cell survival and death, respectively. This study tests the hypothesis that lupus nephritis is associated with alterations of Bcl-2 and Fas protein expression. Thirty-six patients with lupus nephritis and 10 controls (normal individuals) were included in this study. Bcl-2 and Fas positive cells were examined in kidney biopsies by immunohistochemistry. Bcl-2 and Fas serum levels were evaluated by enzyme-linked immunosorbent assay (ELISA). In the glomeruli of normal kidneys, Bcl-2 and Fas proteins were completely absent. In lupus nephritis patients, glomerular expression of Bcl-2 and Fas was seen in mesangial cells (1.3 +/- 0.1 and 2.0 +/- 0.1 for Bcl-2 and Fas, respectively). Similarly, a statistically significantly higher Bcl-2 (217.1 +/- 85.9) and Fas (767.9 +/- 271) serum levels were found in lupus patients compared to controls (148.6 +/- 87, 550.3 +/- 91 for Bcl-2 and Fas, P < 0.05). A direct correlation between serum Bcl-2 and Fas and chronicity index was also found. Compared to normal controls, lupus nephritis is associated with glomerular expression and elevated serum levels of Bcl-2 and Fas proteins. These findings suggest possible roles for Bcl-2 and Fas in glomerular injury during evolution of lupus nephritis. The diagnostic, prognostic and therapeutic ramifications of our findings are open to further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.